China Biotech Services Holdings Limited

SEHK:8037 Stock Report

Market Cap: HK$264.9m

China Biotech Services Holdings Past Earnings Performance

Past criteria checks 0/6

China Biotech Services Holdings has been growing earnings at an average annual rate of 47.7%, while the Healthcare industry saw earnings growing at 4.8% annually. Revenues have been growing at an average rate of 40.2% per year.

Key information

47.7%

Earnings growth rate

48.1%

EPS growth rate

Healthcare Industry Growth11.3%
Revenue growth rate40.2%
Return on equity-28.7%
Net Margin-45.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Mar 07
China Biotech Services Holdings Limited's (HKG:8037) Popularity With Investors Under Threat As Stock Sinks 31%

Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

Jan 18
Earnings Not Telling The Story For China Biotech Services Holdings Limited (HKG:8037) After Shares Rise 46%

We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Jan 06
We Think China Biotech Services Holdings (HKG:8037) Might Have The DNA Of A Multi-Bagger

Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

Dec 09
Does China Biotech Services Holdings (HKG:8037) Have A Healthy Balance Sheet?

These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

Aug 24
These 4 Measures Indicate That China Biotech Services Holdings (HKG:8037) Is Using Debt Safely

A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Nov 05
A Look At The Fair Value Of China Biotech Services Holdings Limited (HKG:8037)

Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

Oct 13
Is China Biotech Services Holdings (HKG:8037) A Risky Investment?

What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

Jun 28
What China Biotech Services Holdings Limited's (HKG:8037) 35% Share Price Gain Is Not Telling You

China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

Mar 16
China Biotech Services Holdings (HKG:8037) Could Become A Multi-Bagger

China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Dec 01
China Biotech Services Holdings (HKG:8037) Knows How To Allocate Capital Effectively

Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

Jul 26
Under The Bonnet, China Biotech Services Holdings' (HKG:8037) Returns Look Impressive

China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Apr 05
China Biotech Services Holdings' (HKG:8037) Robust Earnings Are Supported By Other Strong Factors

Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Mar 23
Investors Shouldn't Overlook China Biotech Services Holdings' (HKG:8037) Impressive Returns On Capital

Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Feb 23
Did You Miss China Biotech Services Holdings' (HKG:8037) Whopping 825% Share Price Gain?

Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

Jan 28
Chun-Shun Ko Just Bought 27% More Shares In China Biotech Services Holdings Limited (HKG:8037)

What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

Jan 11
What Is The Ownership Structure Like For China Biotech Services Holdings Limited (HKG:8037)?

The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Dec 08
The Trend Of High Returns At China Biotech Services Holdings (HKG:8037) Has Us Very Interested

Revenue & Expenses Breakdown
Beta

How China Biotech Services Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:8037 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23212-951520
30 Sep 23776332060
30 Jun 231,3471592350
31 Mar 231,5982082450
31 Dec 221,8522582590
30 Sep 221,394742220
30 Jun 2293732040
31 Mar 22854531900
31 Dec 21624191690
30 Sep 216141131590
30 Jun 219991551570
31 Mar 21797541530
31 Dec 20656301440
30 Sep 20564-211300
30 Jun 2062-1051150
31 Mar 2058-1061130
31 Dec 1959-991040
30 Sep 1962-761030
30 Jun 1965-721010
31 Mar 1967-66950
31 Dec 1870-64960
30 Sep 1875-95910
30 Jun 1879-83800
31 Mar 1888-48730
31 Dec 17105-63690
30 Sep 17111-48610
30 Jun 17113-64640
31 Mar 17104-103710
31 Dec 1687-86730
30 Sep 1669-81720
30 Jun 1652-84620
31 Mar 1639-72500
31 Dec 1534-54440
30 Sep 153-36190
30 Jun 1538-21270
31 Mar 1556-43350
31 Dec 1470-75470
30 Sep 14111-85750
30 Jun 1492-84730
31 Mar 1489-79690
31 Dec 1385-60590
30 Sep 1381-44520
30 Jun 1311315520

Quality Earnings: 8037 is currently unprofitable.

Growing Profit Margin: 8037 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 8037 is unprofitable, but has reduced losses over the past 5 years at a rate of 47.7% per year.

Accelerating Growth: Unable to compare 8037's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8037 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (13.4%).


Return on Equity

High ROE: 8037 has a negative Return on Equity (-28.67%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.